264 related articles for article (PubMed ID: 17405999)
1. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
Heath EI; Canto MI; Wu TT; Piantadosi S; Hawk E; Unalp A; Gordon G; Forastiere AA;
Dis Esophagus; 2003; 16(3):177-86. PubMed ID: 14641306
[TBL] [Abstract][Full Text] [Related]
3. Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus.
Shar AO; Gaudard MA; Heath EI; Forastiere AA; Yang VW; Sontag SJ
Contemp Clin Trials; 2009 Jan; 30(1):2-7. PubMed ID: 19013259
[TBL] [Abstract][Full Text] [Related]
4. Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial.
Shar AO; Gaudard MA; Heath EI; Forastiere AA; Yang VW; Sontag SJ
Dis Esophagus; 2008; 21(7):641-4. PubMed ID: 18522640
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention and Barrett's esophagus: decisions, decisions.
Falk GW; Jankowski J
Am J Gastroenterol; 2008 Oct; 103(10):2443-5. PubMed ID: 18775008
[TBL] [Abstract][Full Text] [Related]
6. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
7. Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Hur C; Broughton DE; Ozanne E; Yachimski P; Nishioka NS; Gazelle GS
Am J Gastroenterol; 2008 Oct; 103(10):2432-42. PubMed ID: 18775019
[TBL] [Abstract][Full Text] [Related]
8. Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression?
Fennerty MB
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S30-7. PubMed ID: 12478242
[TBL] [Abstract][Full Text] [Related]
9. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
11. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
[TBL] [Abstract][Full Text] [Related]
12. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.
Limburg PJ; Wei W; Ahnen DJ; Qiao Y; Hawk ET; Wang G; Giffen CA; Wang G; Roth MJ; Lu N; Korn EL; Ma Y; Caldwell KL; Dong Z; Taylor PR; Dawsey SM
Gastroenterology; 2005 Sep; 129(3):863-73. PubMed ID: 16143126
[TBL] [Abstract][Full Text] [Related]
13. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
14. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.
Cameron AJ; Carpenter HA
Am J Gastroenterol; 1997 Apr; 92(4):586-91. PubMed ID: 9128304
[TBL] [Abstract][Full Text] [Related]
16. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
17. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
18. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
19. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
20. [The clinical strategy for the Barrett's esophagus].
Kitabatake S; Niwa Y; Goto H
Nihon Rinsho; 2005 Aug; 63(8):1434-7. PubMed ID: 16101235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]